Drug Profile

SY 13380

Alternative Names: SY-13380

Latest Information Update: 30 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shouyao Holdings
Class Antineoplastics; Heterocyclic compounds
Mechanism of Action KMT2A protein inhibitors; Menin inhibitors; Protein-protein interaction inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Acute myeloid leukaemia

Most Recent Events

16 Jun 2025 Shouyao Holdings has patents pending for SY 13380 in China, prior to June 2025
25 Apr 2025 Preclinical trials in Acute myeloid leukaemia in China (unspecified route)
25 Apr 2025 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trials in Acute myeloid leukaemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com